Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and ...
Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated ...
StockStory.org on MSN
Moderna (MRNA) shares skyrocket, what you need to know
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, ...
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results